Format

Send to

Choose Destination
Blood Rev. 2014 Jul;28(4):135-42. doi: 10.1016/j.blre.2014.03.002. Epub 2014 Mar 22.

Hemophagocytic syndromes--an update.

Author information

1
Pediatric Hematology and Oncology, University Medical Center Eppendorf, Hamburg, Germany. Electronic address: janka@uke.uni-hamburg.de.
2
Pediatric Hematology and Oncology, University Medical Center Eppendorf, Hamburg, Germany.

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome and not an independent disease. HLH represents the extreme end of a severe uncontrolled hyperinflammatory reaction that can occur in many underlying conditions. Genetic forms of HLHs are due to defects in transport, processing and function of cytotoxic granules in natural killer cells and cytotoxic T lymphocytes, and are not restricted to manifestation in childhood. Acquired forms of HLH are encountered in infections, autoinflammatory and autoimmune diseases, malignancies, acquired immune deficiency. Functional tests allow for differentiation between genetic and acquired HLH. Treatment aims at suppressing hypercytokinemia and eliminating activated and infected cells. It includes immunomodulatory and immunosuppressive agents, cytostatics, T-cell and cytokine antibodies. In genetic HLH cure can only be achieved with hematopoietic stem cell transplantation. Reduced-intensity conditioning regimens have considerably improved survival.

KEYWORDS:

Adult HLH; Hemophagocytic lymphohistiocytosis; Immune deficiency; Macrophage activation syndrome; Reduced-intensity conditioning; Stem cell transplantation

PMID:
24792320
DOI:
10.1016/j.blre.2014.03.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center